Provider Perspectives on Managing EGFRm NSCLC
September 17th 2025Panelists discuss how dermatologic adverse events with EGFR inhibitors are more severe than previously seen with third-generation tyrosine kinase inhibitors, requiring reactive management strategies including topical steroids, antibiotics, and dermatologic consultations that are often difficult to obtain.
First-Line Treatment Selection
September 15th 2025Panelists discuss how treatment selection for a typical intermediate-risk patient with clear cell renal cell carcinoma (RCC) involves choosing between ipilimumab plus nivolumab for long-term durable responses in nonsymptomatic patients and immunotherapy-tyrosine kinase inhibitor (IO-TKI) combinations for those requiring rapid disease control or cytoreduction.
Challenges in Treating Non–Clear Cell RCC
September 12th 2025Panelists discuss how non–clear cell renal cell carcinoma (RCC) represents a challenging, heterogeneous collection of rare tumors comprising 25% to 30% of all RCC cases, requiring careful histological review and individualized risk stratification based on tumor biology, disease tempo, and burden rather than traditional treatment algorithms used for clear cell RCC.
Introducing KEYNOTE-B61 in Non–Clear Cell RCC
September 12th 2025Panelists discuss how they will review the KEYNOTE-B61 phase 2 study examining pembrolizumab plus lenvatinib for previously untreated advanced non–clear cell renal cell carcinoma (RCC), including an overview of non–clear cell RCC and integration of the 3-year follow-up data into clinical practice.
Overview of the Second-Line nccRCC Treatment Landscape
September 12th 2025Panelists discuss the challenges of treating non–clear cell renal cell carcinoma (nccRCC) after first-line progression, emphasizing the limited second-line options, the emerging use of immunotherapy (IO) and combination regimens, the need for subtype-specific strategies, and the critical role of clinical trial enrollment to advance care in this heterogeneous disease.
Overview of the First-Line nccRCC Treatment Landscape
September 12th 2025Panelists discuss recent advances in non–clear cell renal cell carcinoma (nccRCC) treatment, highlighting the emerging role of immunotherapy plus tyrosine kinase inhibitor (TKI) combinations—particularly lenvatinib and pembrolizumab—in improving response rates, progression-free survival, and overall survival across diverse subtypes, while emphasizing individualized care and proactive management.